Neoadjuvant chemotherapy has been combined with anti-angiogenic drugs in metastatic colon cancer patients, treated with Bevacizumab, a humanized monoclonal antibody that targets the vascular endothelial growth factor (VEGF) [94], which is an important angiogenic factor in primary and metastatic human CRC [95]. The gene discussed is VEGFA; the disease is colorectal carcinoma.